Mark Chastain is a Dermatology physician. OpenAlex indexes 14 publications with 484 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
56.1%First-generation cephalosporins44.6%Cephalexin100%Part D≥1293 patientsTetracycline-class Drug7.4%Doxycycline Hyclate100%Part D≥220 patients+ 4 more classes in this area
Nervous system
28.5%Opioid Agonist28.5%Tramadol Hcl100%Part D≥875 patientsCancer & immunology
7.6%Porphyrin Precursor6.8%Aminolevulinic acid hcl100%Part B, office-administered≥149 patientsNucleoside Metabolic Inhibitor0.8%Fluorouracil100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Angiotropic Neonatal Congenital Melanocytic Nevus: How Extravascular Migration of Melanocytes may Explain the Development of Congenital Nevi
American Journal of Dermatopathology
2010 - Improvement of Cystic Fibrosis During Treatment With Isotretinoin
SKINmed Dermatology for the Clinician
2006 - The Glucagonoma Syndrome: A Review of its Features and Discussion of New Perspectives
The American Journal of the Medical Sciences
2001 - HIV Lipodystrophy: Review of the Syndrome and Report of a Case Treated with Liposuction
Dermatologic Surgery
2001
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”